The U.S. District Court for the District of Columbia should reject the Department of Health and Human Services’ request to devise on its own timeline a remedy for its 2018 and 2019 underpayments to 340B hospitals, with no limitations and no oversight by the court, AHA told the D.C. court yesterday. 
 
“Despite conceding that it has maintained an unlawful payment policy for five years, underpaying 340B hospitals by billions of dollars, HHS steadfastly refuses to recognize its obligation to promptly repay Plaintiffs and their members,” AHA wrote in a brief replying to the government’s response to the court. “And despite having now had years to devise a remedy in the event of an adverse final decision—and more than three months since the Supreme Court’s ruling—HHS displays absolutely no urgency about implementing a remedy. … Defendants should not be allowed to deny already-suffering hospitals the vital funding to which they are legally entitled. This Court should retain jurisdiction to provide sufficient oversight to ensure HHS promptly effectuates an appropriate remedy.”    
 
Following its unanimous victory in the U.S. Supreme Court this summer, AHA last month asked the district court to order HHS to immediately stop underpaying certain hospitals that participate in the 340B program and promptly repay them for the unlawful cuts since 2018 without penalizing other hospitals. AHA’s August brief noted that nothing in the 340B law authorizes HHS to retrospectively take back these funds, and in similar circumstances HHS has never recouped funds already spent without explicit congressional authorization, which does not exist here. 

Related News Articles

Headline
AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the…
Headline
AHA March 12 released a new report from Healthsperien on discounts to 340B hospitals through the 340B Drug Pricing Program relative to drug company revenues…
Headline
The U.S. Court of Appeals for the 8th Circuit March 12 upheld Arkansas’ 340B Drug Pricing Nondiscrimination Act against a constitutional challenge brought by…
Headline
AHA Feb. 29 filed a friend-of-the-court brief in support of a Louisiana law that prohibits drug companies from denying Louisiana hospitals the same 340B…
Blog
A new study published in the New England Journal of Medicine demonstrates a stunning lack of understanding of the 340B drug pricing program and the…
Headline
A bipartisan group of senators Feb. 2 released for stakeholder feedback a discussion draft of legislation to clarify in statute Congress’ intent for the 340B…